Skip to main content
PMC home page
Environmental Health and Preventive Medicine logoLink to Environmental Health and Preventive Medicine
. 1999 Apr;4(1):49–53. doi: 10.1007/BF02931250

Sensitive pupil response of early-onset alzheimer’s patients to a dilute mixture of cholinergic antagonist and α-Adrenergic stimulant

Ayumi Takagi 1,✉, Masaru Miyao 1,2,✉, Shin’ya Ishihara 1,✉, Hisataka Sakakibara 1,✉, Takaaki Kondo 1,✉, Hideaki Toyoshima 1,✉, Kazuhiko Kono 4,5,✉, Akihisa Iguchi 4,✉
PMCID: PMC2723423  PMID: 21432171

Abstract

To investigate possible differences in pupil dilation and light reflex in Alzheimer’s disease patients that can be attributed to the age of onset of the disease, a statistical comparison was made of pupil dilation and light reflex among early- and late-onset Alzheimer’s disease, Down syndrome, and patients with vascular dementia, and normal controls. The subjects included 53 probable Alzheimer’s disease outpatients, including both early-onset type (AD: n=21) and late-onset type (SD: n=32). They were compared with normal controls (n=15), Down syndrome patients (DS: n=6), and patients with vascular dementia (VD: n=9). All subjects and controls were dark-eyed Japanese. Pupil dilation and light reflex were tested in 21 AD and 32 SD patients, and were compared with those in the control subjects; 6 DS and 9 VD patients. The measured maximum increase in pupil diameter after instilling a mixture of anticholinergic and α -adrenergic stimulating drugs (Midrin-P®), in one eye was significantly greater in AD and DS than in the controls. However, there was no difference among SD, VD, and controls, suggesting a stronger pupil response to these drugs in AD than in SD. Pupil movement in response to light became significantly smaller and faster after instillation of the drugs in Alzheimer’s disease patients. The above findings may be useful for the early detection of Alzheimer’s disease.

Keywords: Alzheimer’s disease, Down syndrome, pupil, tropicamide, light reflex

References

  • 1).Scinto LF, Daffner KR, Dressler D, et al. A potential noninvasive neurobiological test for Alzheimer’s disease. Science 1994; 266:1051–4. [DOI] [PubMed]
  • 2).Loupe DN, Newman NJ, Green RC, et al. Pupillary response to tropicamide in patients with Alzheimer disease. Ophthalmology 1996; 103:495–503. [DOI] [PubMed]
  • 3).Treloar A, Assin M, Macdonald A. Detecting Alzheimer’s disease [letter]. Science 1995; 267 (5204) 1578. [DOI] [PubMed]
  • 4).Arai H, Terajima M, Nakagawa T, Higuchi S, Mochizuki H, Sasaki H. Pupil dilatation assay by tropicamide is modulated by apolipoprotein E4 allele dosage in Alzheimer’s disease. Neuroreport 1996; 7:918–20. [DOI] [PubMed]
  • 5).Growdon JH, Graefe K, Tennis M, Hayden D, Schoenfeld D, Wray SH. Pupil dilation to tropicamide is not specific for Alzheimer disease. Arch Neurol 1997; 54:841–4. [DOI] [PubMed]
  • 6).Kardon RH. Drop the Alzheimer’s drop test. Neurology. 1998:50:588–91. [DOI] [PubMed]
  • 7).Takagi A, Ishihara S, Kondo T, et al. Age effects on pupil dilation among Alzheimer’s patients [letter]. J Am Geriat Soc; in press. [DOI] [PubMed]
  • 8).McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34:939–44. [DOI] [PubMed]
  • 9).Potter H. Review and hypothesis: Alzheimer disease and Down syndrome—Chromosome 21 nondisjunction may underlie both disorders. Am J Hum Genet 1991; 48:1192–200. [PMC free article] [PubMed]
  • 10).Hardy J, Goate A, Owen M, Rossor M. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet 1989; ii:743. [DOI] [PubMed]
  • ll).Coyle JT, Oster-Granite ML, Gearhart JD. The neurobiologic consequences of Down syndrome. Brain Res Bull 1986; 16:773–87. [DOI] [PubMed]
  • 12).Berg JM, Brandon MWG, Kirman BH. Atropine in Mongolism. Lancet 1959; ii:441–2. [DOI] [PubMed]
  • 13).Priest JH. Atropine response of the eyes in mongolism. Am J Dis Child 1960; 100:869–72. [DOI] [PubMed]
  • 14).Sacks B, Smith S. People with Down’s syndrome can be distinguished on the basis of cholinergic dysfunction. J Neurol Neurosurg Psychiatr 1989; 52:1294–5. [DOI] [PMC free article] [PubMed]
  • 15).Jones R. Do women and myopes have larger pupils? Investigative Ophthalmology & Visual Science. 1990; 31(7):1413–5. [PubMed]
  • 16).Winn B, Whitaker D, Elliot DB, Phillips NJ. Factors affecting light-adapted pupil size in normal human subjects. Investigative Ophthalmology & Visual Science. 1994; 35(3):1132–7. [PubMed]
  • 17).The American Psychiatric Association: DSM-III-R, The American Psychiatric Association Washington, DC, 1987, pp. 103–9.
  • 18).Kato S, Hasegawa K, Shimogaki H, Onodera A. Establishment of Hasegawa Dementia Scale Revised (HDS-R). Ronen-Seishin-Igaku-Zasshi 1991; 2:1339–47, (in Japanese).
  • 19).Corey-Bloom J, Thal LJ, Galasko D, et al. Diagnosis and evaluation of dementia. Neurology 1995; 45:211–8. [DOI] [PubMed]
  • 20).Pozzessere G, Valle E, Rossi P, et al. Pupillometric evaluation and analysis of light reflex in healthy subjects as a tool to study autonomic nervous system changes with aging. Aging Clin Exp Res 1996; 8:55–60. [DOI] [PubMed]
  • 21).Piha SJ, Halonen JP. Infrared pupillometry in the assessment of autonomic function. Diabetes Research and Clinical Practice 1994; 26:61–6. [DOI] [PubMed]

Articles from Environmental Health and Preventive Medicine are provided here courtesy of The Japanese Society for Hygiene

RESOURCES